- Revelation Biosciences ( NASDAQ: REVB ) is trading 45.7% higher premarket after it announced an exclusive license agreement with Vanderbilt University, Nashville to develop and commercialize its drug, phosphorylated hexaacyl disaccharide (PHAD), for treating or preventing infections.
- The license covers potential applications such as prevention or reduction of acquired infections including those resulting from surgery, severe burns, and antibiotic resistance.
- Preclinical studies have shown treatment with PHAD significantly reduces the duration and severity of infection by augmenting the innate immune response, a form of trained immunity.
For further details see:
Revelation Biosciences surges 46% on licensing deal with Vanderbilt University